Washington – October 04, 2026 -- Shanghai Media Group staged a cultural and investment outreach event on the National Mall on October 3, 2026, drawing nearly 100 political, business, technology and cultural figures from China and the United States to promote the city as an international economic and trade hub.

Hiroshima – October 3, 2026 -- Ractigen Therapeutics presented first-in-human data showing its systemically delivered small activating RNA (saRNA), RAG-18, produced 3.5- to 5.3-fold increases in sarcolemmal utrophin expression in boys with Duchenne muscular dystrophy (DMD), marking the first clinical proof-of-mechanism for RNA activation (RNAa) in a monogenic disease. The data were disclosed in a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.

Cambridge/Shenzhen – October 02, 2026 -- XtalPi (HKEX: 2228) has moved its proprietary hair loss drug program into IND-enabling studies, with pharmacology, safety, and chemistry, manufacturing and controls (CMC) work underway to support a future Investigational New Drug application.

Vancouver – October 02, 2026 -- Silvercorp Metals Inc. (TSX/NYSE American: SVM) secured shareholder approval for all resolutions at its annual general and special meeting, including a special resolution to amend its corporate Articles to align with Hong Kong Stock Exchange listing rules.

Shenzhen – October 02, 2026 -- An artificial intelligence model jointly developed by XtalPi Holdings Limited (2228.HK) and Fangda Carbon New Material Co., Ltd. (600516.SH) has passed project acceptance testing and entered full operational use within Fangda Carbon's production workflow.

The system ranks raw material formulation candidates before physical trials, meeting the companies' established targets for predictive accuracy, cost optimization, and operational efficiency.

Tianjin, China – October 02, 2026 -- Tianjin University's "Shengong-Shengao" system has become China's first approved brain-computer interface (BCI) medical device for diagnosing cognitive impairment, cutting diagnosis time for conditions like hydrocephalus from days to just 30 minutes. The milestone marks a commercial breakthrough as TJU, China's first modern university, marks its 131st anniversary on October 2, 2026.

Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.

The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.

Beijing – October 02, 2026 -- iQIYI's AIGC film series "The Ferry Man" has generated cumulative revenue-sharing earnings exceeding RMB 8 million (US$1.2 million) as of September 23, validating artificial intelligence as a financially viable film production model. The milestone arrives as the third installment, "The Ferry Man: The Dream of the Princess", debuts October 1 on iQIYI and iQIYI International.

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.